Search results
411 Results for 'Therapeutics'
- Technologies (49)
- Collaborations (4)
- Team (0)
- News (280)
- Pages (0)
- Multimedia (78)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 49
-
DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance. -
NodeTX: Growing lymph nodes to treat cancer
NodeTX is a novel immunotherapy that leverages the human body's innate ability to grow lymph nodes to fight tumors. -
Immunostimulatory RNA Therapeutic for Treatment of Cancer and Infectious Disease
Our novel dsRNAs stimulate the immune system to inhibit cancer, bacterial, and viral infections including SARS-CoV-2 and multiple influenza strains.
Collaborations 4
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss Brain Targeting Program
Advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics. -
i3 Center: Biomaterials to Create T Cell Immunity
Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.
News 280
Multimedia 78
-
Video/AnimationAminoX: Making Better Protein Drugs, Quicker and CheaperA synthetic biology and advanced chemistry platform that efficiently incorporates non-standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University -
Video/AnimationMice Don’t Menstruate: Reimagining Women’s Health Using Organ Chips with Dr. Donald IngberIn this episode, host Sharon Kedar, Co-Founder of Northpond Ventures, is joined by Dr. Donald Ingber, Founding Director at Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr. Ingber’s commitment to following his passion has led him to countless medical and technological breakthroughs, including Organ Chip technology. These incredible chips recreate the structure and... -
Video/AnimationAtlantic Health Research Spotlight: Finding Balance in Bipolar Disorder Through Drug Prediction and Organoid-Based Drug ScreeningInnovation has disrupted care as we know it. Challenges with access, complex diseases, and care delivery persist, but so do areas of opportunity for emerging tech and discoveries. The Atlantic explored gene editing, artificial intelligence, climate change, weight-loss and diabetes treatments, and more at their Annual Health Summit. The Wyss’ Director of Synthetic Biology, Jenny... -
Video/AnimationReimagine the World – Volume 3 – Northpond EditionThe Wyss Institute’s alliance with Northpond Labs supports early-stage, transformative research with strong translation potential. Hear Northpond Ventures co-founders Michael Rubin and Sharon Kedar explain why they decided to partner with the Wyss, as well as the leaders of various Wyss projects and startups about how support from Northpond has helped accelerate their technologies to... -
Video/AnimationHarborSite AnimationThis animation explains how the Wyss Institute’s HarborSite genome editing technology uses highly specific and efficient recombinase enzymes and genomic safe harbors to achieve more predictable, safe, and durable gene therapies. Credit: Wyss Institute at Harvard University -
Video/AnimationEnhancing Lactation to Improve Infant and Maternal HealthLactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions. Credit: Wyss Institute at Harvard University